ReviewCurrent urology reports2016
Phytotherapy for Benign Prostatic Hyperplasia.
Review in Current urology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2018Pooled it
- Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2017Pooled it
- A two-week, double-blind, placebo-controlled trial of Viola odorata, Echium amoenum and Physalis alkekengi mixture in symptomatic benign prostate hyperplasia (BPH) men.Pharmaceutical biology · 2017Trial
- Natural Products in the Treatment of Lower Urinary Tract Dysfunction and Infection.Handbook of experimental pharmacology · 2025Review
- Bioassay-guided isolation of two antiproliferative metabolites fromFrontiers in pharmacology · 2024Article
- Prostatic Therapeutic Efficacy of LENILUTSPharmaceutics · 2022Article
- Anti-proliferative, Anti-angiogenic and Anti-inflammatory Effects of Moringa peregrina Leaf Extracts on Testosterone- Induced Benign Prostatic Hyperplasia in Rats.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Chemical profiles of the active fraction from Prinsepia utilis Royle leaves and its anti-benign prostatic hyperplasia evaluation in animal models.BMC complementary medicine and therapies · 2021Article
- Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registry.World journal of urology · 2021Observational
- Current Treatment for Benign Prostatic Hyperplasia.Deutsches Arzteblatt international · 2020Review
- Cyclopamine functions as a suppressor of benign prostatic hyperplasia by inhibiting epithelial and stromal cell proliferation via suppression of the Hedgehog signaling pathway.International journal of molecular medicine · 2020Article
- Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase.Scientific reports · 2019Article
- Potential Therapeutic Effects of Underground Parts ofEvidence-based complementary and alternative medicine : eCAM · 2019Article
- Metabolite Profiling of Eastern Teaberry (Gaultheria procumbens L.) Lipophilic Leaf Extracts with Hyaluronidase and Lipoxygenase Inhibitory Activity.Molecules (Basel, Switzerland) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe use of complementary and alternative medications for symptomatic benign prostatic hyperplasia is a lucrative business in the USA with revenues reaching close to US$6.4 billion in sales for the 2014 fiscal year. Yet, despite its popularity, the evidence supporting the continued use of phytotherapy for symptomatic benign prostatic hyperplasia (BPH) is questionable and a topic worth investigation given its wide spread use.
methodsA comprehensive literature search utilizing Medline and PubMed was conducted to identify literature pertaining to phytotherapy for the management of BPH. Agents with at least modest clinical data were selected for in-depth review including Seronoa repens, Pygeum africanum, Secale cereale, and Hypoxis rooperi.
resultsEarly clinical trials for each of the agents demonstrated mixed efficacy results with many studies pointing to a possible benefit for phytotherapy. On further examination of these studies, significant confounders such as poor product standardization, study design, and follow-up duration were identified. More recent, larger and more soundly constructed studies found no significant benefit for the use of phytotherapy in the treatment of BPH.
conclusionsTwenty years ago, the urologic community was encouraged by trial results that suggested phytotherapy could effectively treat symptomatic benign prostatic hyperplasia. Since that time, several well-constructed studies have consistently demonstrated that these agents are no more efficacious than placebo, despite being largely safe for ingestion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.